Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Maze Therapeutics, Inc.

NASDAQ: MAZE · Life Sciences · 8 alerts · CIK 1842295

Share price
$33.90Close, Nov 16
Market cap
$1.85B
Shares outstanding
54.68MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Maze Therapeutics, Inc. filings on SEC EDGAR ↗

4:15 PM ET 10-Q
Financial Results

Maze Therapeutics Q3 2026 Results: Net Loss of $48M, Loss Widens

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on its Compass platform and lead therapeutic candidates MZE829 and MZE782. As of November 4, 2026, the company had 54,683,345 shares of common stock outstanding and continues to report significant operating losses with no product revenue generated to date.

Key figure
Net loss $48M
4:10 PM ET 8-K
Financial Results

Maze Therapeutics Financial Results

Maze Therapeutics reported third quarter 2026 financial results, ending the period with $477 million in cash and a projected runway into 2029. The company highlighted the completion of enrollment for its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease, with data expected in early 2027. Net loss for the quarter was $38.4 million, driven by increased R&D expenses related to its clinical-stage pipeline.

Term
Q3 2026

“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort. HORIZON gives us the opportunity to generate a robust dataset across three distinct AMKD patient populations, including patients with and without diabetes and those with FSGS, and provide a comprehensive view of MZE829’s potential as a best-in-class therapy for a broad AMKD population, supported by its differentiated dual mechanism of action.”

Jason Coloma, Ph.D., chief executive officer of Maze
4:14 PM ET Form 4
Insider Selling

Maze Therapeutics CEO Jason V. Coloma Sells $1.04M of Stock

Jason V. Coloma, CEO, sold 34,501 shares of Maze Therapeutics, Inc. at $30.09 to $31.05 a share (average $30.25) in 4 transactions, worth $1.04M in total on Nov 2, 2026. Shares held after the trade: 186,901 (-2.8%).

Value
$1.04M
Shares
34,501
Average price
$30.25
Role
CEO
Holding change
-2.8%
Trade date
Nov 2, 2026
4:15 PM ET Form 4
Insider Selling

Maze Therapeutics Csbo Atul Dandekar Sells $241K of Stock

Atul Dandekar, Csbo, sold 7,500 shares of Maze Therapeutics, Inc. at $32.07 a share, worth $241K in total on Oct 29, 2026. Shares held after the trade: 32,316 (-18.8%).

Value
$241K
Shares
7,500
Price
$32.07
Role
Csbo
Holding change
-18.8%
Trade date
Oct 29, 2026
4:05 PM ET 8-K
Other 8-K Filing

Maze Therapeutics Other 8-K Filing

Maze Therapeutics entered into an exchange agreement with Frazier Life Sciences to exchange 2,776,007 shares of common stock for pre-funded warrants to purchase an equivalent number of shares. The transaction was conducted under Section 3(a)(9) of the Securities Act, which allows for the exchange of one class of securities for another with no new cash raised.

Counterparty
Frazier Life Sciences Public Fund, L.P.
4:12 PM ET Form 4
Insider Selling

Maze Therapeutics CEO Jason V. Coloma Sells $932K of Stock

Jason V. Coloma, CEO, sold 34,501 shares of Maze Therapeutics, Inc. at $27.02 to $27.02 a share (average $27.02) in 2 transactions, worth $932K in total on Oct 1, 2026. Shares held after the trade: 191,447 (-14.3%).

Value
$932K
Shares
34,501
Average price
$27.02
Role
CEO
Holding change
-14.3%
Trade date
Oct 1, 2026
4:10 PM ET Form 4
Insider Selling

Maze Therapeutics President, R&D & CMO Harold Bernstein Sells $435K of Stock

Harold Bernstein, President, R&D & CMO, sold 16,141 shares of Maze Therapeutics, Inc. at $26.93 a share, worth $435K in total on Oct 1, 2026. Shares held after the trade: 0 (-100.0%).

Value
$435K
Shares
16,141
Price
$26.93
Role
President, R&D & CMO
Holding change
-100.0%
Trade date
Oct 1, 2026
4:07 PM ET Form 4
Insider Selling

Maze Therapeutics Csbo Atul Dandekar Sells $203K of Stock

Atul Dandekar, Csbo, sold 7,500 shares of Maze Therapeutics, Inc. at $27.06 a share, worth $203K in total on Sep 29, 2026. Shares held after the trade: 32,316 (-18.8%).

Value
$203K
Shares
7,500
Price
$27.06
Role
Csbo
Holding change
-18.8%
Trade date
Sep 29, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.